Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?

Abstract

Objectives To analyze whether prescription use of GLP-1RA and SGLT2i in individuals with type 2 diabetes with cardiovascular disease (CVD) has increased after the ADA/EASD consensus guidelines (2018) in a German Real-World setting and which clinical characteristics are associated with prescription use of these drugs.

Methods The Disease Analyzer database (IQVIA) comprises a representative panel of 1,373 general practitioners, diabetologists, and cardiologists throughout Germany (01/2015-12/2020: 12.6 million patients). Newly diagnosed type 2 diabetes (n=45,531) was identified by ICD-10 codes (E11). Matching (1:1) on practice specialty, sex, age, and year of diabetes diagnosis was performed for CVD. Logistic regression models were fitted to obtain adjusted odds ratios (OR) for characteristics associated with prescription use (median follow-up: 1.9 years).

Results Overall, 35% of patients (n=16,006) were treated with glucose-lowering drugs during the first year after type 2 diabetes diagnosis (HbA1c≥7.0%: 80%). GLP-1RA (2.4%) and SGLT2i (8.5%) were rarely prescribed. After the consensus, use of GLP-1RA and SGLT2i increased, however, almost independently of pre-existing CVD (12/2019-11/2020 vs. 12/2017-11/2018: yes, no): GLP-1RA: from 5.7 to 9.2%, 5.2 to 7.6%; SGLT2i: from 13.9 to 20.4%, 12.1 to 16.6%. Among cardiovascular risk factors, the largest OR for GLP-1RA was for obesity (4.5; 95%CI: 3.2–6.3). CVD was moderately related with SGLT2i (1.45; 1.32–1.60) and GLP-1RA (1.35; 1.08–1.69) prescriptions. A weak association was observed between SGLT2i and heart failure (1.18; 95%CI: 1.05–1.32).

Conclusion National prescription use of GLP-1RA and SGLT2i did not come close to the recommendation in subjects with CVD issued by the 2018 ADA/EASD consensus.

Key words

GLP-1RA, SGLT2i - type 2 diabetes - glucose-lowering drugs - cardiovascular disease- guidelines

• References

• 1 Davies MJ, D’Alessio DA, Fradkin J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41: 2669-2701
• 2 Gabler M, Geier S, Mayerhoff L. et al. Cardiovascular disease prevalence in type 2 diabetes – an analysis of a large German statutory health insurance database. BMC Public Health 2021; 21: 328
• 3 Cefalu WT, Kaul S, Gerstein HC. et al. Cardiovascular outcomes trials in type 2 diabetes: Where do we go from here? Reflections from a diabetes care editors’ expert forum. Diabetes Care 2018; 41: 14-31
• 4 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322
• 5 Leiter LA, Bain SC, Hramiak I. et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: A post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol 2019; 18: 73
• 6 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130
• 7 Verma S, Fainberg U, Husain M. et al. Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide. Diabetes Obes Metab 2021; 23: 1677-1680
• 8 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
• 9 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657
• 10 Knudsen JS, Baggesen LM, Lajer M. et al. Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study. PLoS One 2020; 15: e0229621
• 11 Farmer RE, Beard I, Raza SI. et al. Prescribing in type 2 diabetes patients with and without cardiovascular disease history: A descriptive analysis in the UK CPRD. Clin Ther 2021; 43: 320-335
• 12 Mosenzon O, Alguwaihes A, Leon JLA. et al. CAPTURE: A multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol 2021; 20: 154
• 13 Mata-Cases M, Franch-Nadal J, Real J. et al. Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: Data from a Mediterranean population database. Prim Care Diabetes 2021; 15: 588-595
• 14 Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009; 47: 617-626
• 15 Rathmann W, Bongaerts B, Carius HJ. et al. Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther 2018; 56: 459-466
• 16 Landgraf R, Aberle J, Birkenfeld AL. et al. Therapie des typ-2-diabetes. Diabetologie 2021; 16: S168-S206 [in German]
• 17 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale Versorgungs Leitlinie Typ-2-Diabetes – Teilpublikation der Langfassung, 2. Auflage. Version 1. 20 [in German]
• 18 Nauck MA, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab 2021; 46: 101102
• 19 Brown E, Wilding JPH, Alam U. et al. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. Ann Med 2021; 53: 2072-2089
• 20 Zelniker TA, Wiviott SD, Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31-39
• 21 Abd El Aziz MS, Kahle M, Meier JJ. et al. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 2017; 19: 216-227
• 22 Kostev K, Rathmann W. Influence of macro- and microvascular comorbidity on time to insulin initiation in type 2 diabetes patients: A retrospective database analysis in Germany, France, and UK. Prim Care. Diabetes 2013; 7: 167-171
• 23 Li S, Vandvik PO, Lytvyn L. et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: A clinical practice guideline. BMJ 2021; 373: n1091
• 24 Palmer SC, Tendal B, Mustafa RA. et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ 2021; 372: m4573
• 25 Buhse S, Kuniss N, Liethmann K. et al. Informed shared decision-making programme for patients with type 2 diabetes in primary care: Cluster randomised controlled trial. BMJ Open 2018; 8: e024004
• 26 Shin H, Schneeweiss S, Glynn RJ. et al. Trends in first-line glucose-lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA. Diabetes Care 2021; 44: 1774-1782
• 27 McCoy RG, Van Houten HK, Deng Y. et al. Comparison of diabetes medications used by adults with commercial insurance vs medicare advantage, 2016 to 2019. JAMA Netw Open 2021; 4: e2035792
• 28 Falkentoft AC, Andersen J, Malik ME. et al. Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a Danish nationwide observational study. Lancet Reg Health Eur 2022; 14: 100308
• 29 Antidiabetics. Drug information from the AOK Lower Saxony https://www.aok.de/gp/wirtschaftliche-verordnung/aktuelle-arzneimittelinformationen-der-aok-niedersachsen/orale-antidiabetika Accessed: December 22, 2021